Compare Gilead Sciences, Inc. (GILD) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Oatly Group AB - ADR — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Oatly Group AB - ADR trades at $10.52 (market cap $330.93M). The key difference: Gilead Sciences, Inc. is far larger — about 551.2× Oatly Group AB - ADR's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Oatly Group AB - ADR for 18 Days on average.
| GILD | OTLY | |
|---|---|---|
Market Cap | $182.40B | $330.93M |
Volume | 4,469,821 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $15.91 |
52-Week Low | $116.74 | $8.03 |
Typical Hold Time | 111 Days | 18 Days |
Enterprise Value | $205.46B | $835.34M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
OTLY trades at $10.37, down 1.33% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported Q2 2026 revenue growth and raised full-year guidance, though it continues to post significant net losses. Analyst sentiment is divided with a $12.28 consensus price target representing 18% upside potential. Cash flow remains negative but improving, with operating losses narrowing from -$269M in 2022 to -$24M in 2025.
The investment case hinges on OTLY's revenue growth acceleration and path to profitability, but high debt levels and persistent losses present substantial risk. While the stock offers potential upside to analyst targets, investors must weigh the company's improving operational trends against its negative equity and cash burn. The upcoming Q3 2026 earnings report on October 28 will be critical for validating management's turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
